Atrasentan HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200370

CAS#: 195733-43-8 (HCl)

Description: Atrasentan, also known as ABT-627, is a orally available ETA receptor antagonist with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.

Chemical Structure

Atrasentan HCl
CAS# 195733-43-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 200370
Name: Atrasentan HCl
CAS#: 195733-43-8 (HCl)
Chemical Formula: C29H39ClN2O6
Exact Mass:
Molecular Weight: 547.09
Elemental Analysis: C, 63.67; H, 7.19; Cl, 6.48; N, 5.12; O, 17.55

Price and Availability

Size Price Availability Quantity
500.0mg USD 8950.0 2 Weeks
1.0g USD 14650.0 2 Weeks
Bulk inquiry

Related CAS #: 195733-43-8 (HCl)   173937-91-2 (free base)    

Synonym: (+)A 127722; A 127722; ABT627; ABT 627; ABT-627; NSC720763; A147627; Abbott 147627; US brand name: Xinlay;

IUPAC/Chemical Name: (2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride.


InChi Code: InChI=1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1

SMILES Code: O=C([C@H]1[C@H](C2=CC=C(OC)C=C2)N(CC(N(CCCC)CCCC)=O)C[C@@H]1C3=CC=C(OCO4)C4=C3)O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 547.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ritter C, Zhang S, Finch JL, Liapis H, Suarez E, Ferder L, Delmez J, Slatopolsky E. Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats. Kidney Blood Press Res. 2014;39(4):340-52. doi: 10.1159/000355811. Epub 2014 Sep 19. PubMed PMID: 25300759; PubMed Central PMCID: PMC4225010.

2: Vaněčková I, Dobešová Z, Kuneš J, Vernerová Z, Zicha J. Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet. J Hypertens. 2015 Jan;33(1):161-9. doi: 10.1097/HJH.0000000000000357. PubMed PMID: 25255392.

3: de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10. PubMed PMID: 24722445; PubMed Central PMCID: PMC4005314.

4: Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs G, Peer CJ, Petros WP. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2014 May;73(5):991-7. doi: 10.1007/s00280-014-2432-x. Epub 2014 Mar 12. PubMed PMID: 24619498; PubMed Central PMCID: PMC4010098.

5: Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10. PubMed PMID: 24616308; PubMed Central PMCID: PMC3970171.

6: Taneja SS. Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. J Urol. 2014 Mar;191(3):656. doi: 10.1016/j.juro.2013.11.085. Epub 2013 Nov 28. PubMed PMID: 24522033.

7: Atrasentan of no benefit to men with metastatic prostate cancer. Bonekey Rep. 2014 Jan 15;3:503. doi: 10.1038/bonekey.2013.237. eCollection 2014 Jan 15. PubMed PMID: 24466420; PubMed Central PMCID: PMC3899568.

8: Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17. PubMed PMID: 23871417; PubMed Central PMCID: PMC4277263.

9: Wan KX, Reimer MT, Metchkarova MP, Richter AJ, Paramadilok A, Kavetskaia O, El-Shourbagy T. Toxicokinetic evaluation of atrasentan in mice utilizing serial microsampling: validation and sample analysis in GLP study. Bioanalysis. 2012 Jun;4(11):1351-61. doi: 10.4155/bio.12.91. PubMed PMID: 22720653.

10: Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 2012 Oct 15;91(13-14):739-42. doi: 10.1016/j.lfs.2012.01.011. Epub 2012 Feb 2. PubMed PMID: 22326504.

Additional Information

195733-43-8 (Atrasentan HCl)
173937-91-2 (Atrasentan free base).

Atrasentan hydrochloride  is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.
According to, [Cancer. 2007 Nov 1;110(9):1959-66.] A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Carducci MA, Saad F, brahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB; for the Atrasentan Phase III Study Group Institutions. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5-8, 2004. The conclusion states that Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.